NASDAQ$HOLX

Hologic Inc · Q4 2025 earnings

Q4 2025 earnings · · After market close · Investor relations

Briefing

Hologic reported fiscal Q4 2025 revenue of $1.05B with GAAP diluted EPS of $0.83.

Fourth-quarter revenue increased 6.2% to $1.05 billion. GAAP diluted EPS was $0.83 and non-GAAP diluted EPS was $1.13 as diagnostics, breast health, and surgical segments grew organic revenue excluding COVID and divestitures.

  • Fiscal Q4 revenue $1.05B (+6.2% YoY).
  • GAAP diluted EPS $0.83; non-GAAP EPS $1.13.
  • Organic growth ex-COVID and divestitures mid-single digits.
  • Capital deployment and tariff impacts discussed on call.

Headline financials

Total Revenue

$1.05B

Previous: $988M+6.2%
EPS (adj)

$1.13

Previous: $1.01+11.9%
GAAP Gross Margin

55.6%

Previous: 56.5%-1.6%
Non-GAAP Gross Margin

60.9%

Previous: 61.5%-1.0%
Operating Margin

22.6%

Previous: 23.3%-3.0%
Non-GAAP Operating Margin

31.2%

Previous: 30.0%+4.0%
Net Margin

17.9%

Previous: 18.1%-1.1%
Non-GAAP Net Margin

24.3%

Previous: 24.0%+1.3%
Net Income

$187M

Previous: $178.60+104871120.6%
Operating Income

$237M

Previous: $230.10+102998596.2%
Gross Profit

$584M

Previous: $557.70+104626043.1%

Revenue & EPS history

Hologic · Revenue · Quarterly

$1.05B

Q4 2025+6.2%vs Q4 2024
Beat estimate in 14 of 16 quarters(88%)
ActualEstimate

Revenue by segment

Hologic · $769M total across 2 segments · Q4 2023

  • Diagnostics
    $416M-20.1%
  • Breast Health
    $353M+28.2%

Forward guidance

Hologic discussed fiscal 2026 outlook emphasizing organic growth, productivity, and capital returns while managing tariff and FX headwinds.

Tailwinds

  • Non-GAAP diluted EPS $1.13 (+11.9% YoY) in fiscal Q4.
  • Organic revenue growth excluding COVID and divestitures.
  • Interventional breast and surgical product momentum.

Headwinds

  • Diagnostics COVID-related revenue continues to decline.
  • Tariff and currency impacts on international sales.
  • Capital equipment cycles can affect breast health placements.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q4 2025

Historical avgQ4 2025

-0.5%

Avg return

Earnings day

+0.2%

Avg return

5 days after

-0.1%

Avg return

30 days after

49%

35 / 72 earnings

Positive

+12.3%

Q3 2020

Best reaction

-11.4%

Q2 2012

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q2 2026
Q1 2026+0.0%-0.6%+0.7%
Q4 2025+0.1%+0.1%+1.1%
Q3 2025+2.8%+4.4%+3.3%
Q2 2025-5.6%-3.2%+8.5%
Q1 2025-10.1%-11.4%-11.3%
Q4 2024-4.3%-4.3%-6.6%
Q3 2024+4.9%+6.4%+2.2%
Q2 2024+0.3%-0.2%-3.3%
Q1 2024-2.7%-0.4%-1.1%
Q4 2023+5.7%+5.4%+0.1%
Q3 2023-5.1%-5.9%-5.4%
Q2 2023-2.4%-2.6%-8.3%
Q1 2023+3.8%+3.6%-1.1%
Q4 2022+10.8%+12.4%+13.8%
Q3 2022+1.0%+1.3%-3.4%
Q2 2022+1.2%+3.4%+9.8%
Q1 2022+4.0%+3.8%+2.4%
Q4 2021-3.3%-5.9%-0.3%
Q3 2021+2.3%+5.0%+9.7%
Q2 2021-9.1%-9.9%-13.4%
Q1 2021+1.7%+11.2%-3.3%
Q4 2020+6.6%-5.0%+1.7%
Q3 2020+12.3%+14.8%-2.8%
Q2 2020+2.9%+2.6%+8.9%
Q1 2020-0.7%-1.8%-13.7%
Q4 2019-4.0%+8.8%+10.3%
Q3 2019-1.3%-6.5%-4.1%
Q2 2019-0.1%+0.7%-5.1%
Q1 2019+0.6%-0.5%+8.6%
Q4 2018+4.9%+1.2%+3.7%
Q3 2018-3.5%-1.9%-7.5%
Q2 2018-6.9%-6.8%-3.9%
Q1 2018-6.7%-6.6%-2.2%
Q4 2017+0.4%+2.9%+8.1%
Q3 2017-9.3%-11.3%-12.5%
Q2 2017-4.3%-5.1%-2.0%
Q1 2017-2.6%-2.9%+1.8%
Q4 2016+4.3%+8.5%+6.3%
Q3 2016+3.9%+5.8%+5.3%
Q2 2016-10.0%
Q1 2016-9.2%
Q4 2015+0.6%
Q3 2015+8.6%
Q2 2015+2.1%
Q1 2015+5.1%
Q4 2014-1.7%
Q3 2014+2.1%
Q2 2014+8.1%
Q1 2014-5.9%
Q4 2013-6.9%
Q3 2013-0.2%
Q2 2013+0.1%
Q1 2013-4.1%
Q4 2012-0.3%
Q3 2012-0.4%
Q2 2012-11.4%
Q1 2012+5.2%
Q4 2011-4.0%
Q3 2011-3.9%
Q2 2011-0.6%
Q1 2011+0.0%
Q4 2010+1.2%
Q3 2010+1.2%
Q2 2010-2.6%
Q1 2009-2.8%
Q1 2010-1.1%
Q2 2009+2.9%
Q4 2007+2.9%
Q4 2009+2.9%
Q3 2009-3.0%
Q3 2008-3.0%
Q4 2008-3.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro